PGDx has developed a portfolio of standardized tissue-based and liquid biopsy next-generation sequencing (NGS) assays for laboratories worldwide, featuring automated bioinformatics that ensures consistent results and quality of testing. By automating the data analysis process, PGDx is enabling the scalability of precision medicine with a fast, reliable, and accurate system.
Our portfolio of NGS assays works in all solid tumors to identify clinically actionable and guideline supported biomarkers to inform treatment decisions for patients with advanced cancer. With an in-house testing option, PGDx is empowering healthcare professionals to more rapidly identify patients’ unique biomarkers and inform care pathways that optimize treatment options for patients.
Ability to utilize local laboratory and pathologist expertise
Avoid send out testing
Maintain ownership of valuable samples, data, and patient results
Deliver actionable results in as little as 4-5 days
Manage testing schedule and lab priorities
Faster turnaround time to reliable results, enabling the best and most informed treatment decisions